Not 100% comparing apples with apples, but it does appear ciltacabtagene autoleucel (cilta-cel), will over time become 1st line treatment, where its currently on 3rd line treatment.
https://www.cancernetwork.com/view/adjusted-comparison-of-cilta-cel-vs-standard-regimens-reveals-favorable-outcomes-in-triple-class-exposed-multiple-myeloma
Not 100% comparing apples with apples, but it does appear...
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.26 |
Change
-0.045(3.46%) |
Mkt cap ! $208.5M | |||
| Open | High | Low | Value | Volume |
| $1.30 | $1.30 | $1.25 | $77.93K | 61.51K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1861 | $1.26 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.30 | 5256 | 1 |
View Market Depth
| Last trade - 16.10pm 30/04/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.25 |
Change
-0.045 ( 1.91 %) |
||||
| Open | High | Low | Volume | ||
| $1.27 | $1.29 | $1.25 | 5875 | ||
| Last updated 15.55pm 30/04/2024 ? | |||||
| RAC (ASX) Chart |